Nvidia-backed AI drug developer Iambic raises $150m in IPO
Tech in Asiaen
Iambic said it will use the proceeds to advance three early-stage cancer drug candidates.
This is a short summary published by AI Global Wire. The full article is owned and hosted by Tech in Asia — open it there to read it in full.
Read the full story at Tech in Asia- Företag
Related AI news
- New York City pension fund asks Anthropic to delay IPOEconomic Times Tech · October 16, 2026
- Deep Reinforcement Learning for HPC Job Scheduling: A Statistical EvaluationarXiv cs.AI · October 16, 2026
- When Reasoning Traces Conflict with Evidence: How Answer Configuration Shapes Evidence FollowingarXiv cs.AI · October 16, 2026
- Value-Informed Schedule Trimming for Accelerated Sequential Monte Carlo Guidance in Discrete DiffusionarXiv cs.AI · October 16, 2026
- Evolving Together, Failing Apart: The Skill-Policy Co-evolution Trap in Self-Improving AgentsarXiv cs.AI · October 16, 2026
- MAI-Gym: An Open All-in-One Platform for GUI Agent Evaluation and RL Training across Mobile and Computer EnvironmentsarXiv cs.AI · October 16, 2026